Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al.

Tackling TKI resistance in AML: A commentary on “Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.” by Yamatani et al.

Bibliographic Details
Main Authors:	Özden Hatırnaz Ng, Ahmet Emre Eşkazan
Format:	Article
Language:	English
Published:	Elsevier 2022-05-01
Series:	Translational Oncology
Subjects:	Acute myeloid leukemia AML FLT3 FLT3-ITD/D835 BCL2A1 Resistance
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523322000560

Similar Items

FLT3-ITD Incidence and FLT-D835 Mutations in Acute Myeloid Leukemia Patients with Normal Karyotype in Morocco: A Preliminary Study
by: Hind Dehbi, et al.
Published: (2013-01-01)

FLT3/ITD associated with an immature immunophenotype in PML-RARα leukemia
by: Mariko Takenokuchi, et al.
Published: (2012-10-01)

Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML
by: Franziska Schmidt, et al.
Published: (2022-11-01)

Are cup-like blasts specific to AML patients with FLT3 ITD and a normal karyotype? An ALL case report and review of the literature
by: Özgür Mehtap, et al.
Published: (2011-06-01)

Are cup-like blasts specific to AML patients with FLT3 ITD and a normal karyotype? An ALL case report and review of the literature
by: Özgür Mehtap, et al.
Published: (2011-05-01)

Study of HOTAIR LncRNA in AML patients in context to FLT3-ITD and NPM1 mutations status
by: Mona Salah, et al.
Published: (2021-06-01)

Deacetylation of YAP1 Promotes the Resistance to Chemo- and Targeted Therapy in FLT3-ITD+ AML Cells
by: Panpan Feng, et al.
Published: (2022-05-01)

Role of Biomarkers in FLT3 AML
by: Nitika, et al.
Published: (2022-02-01)

Rational design and synthesis of 2-(1H-indazol-6-yl)-1H-benzo[d]imidazole derivatives as inhibitors targeting FMS-like tyrosine kinase 3 (FLT3) and its mutants
by: Daseul Im, et al.
Published: (2022-12-01)

Comparison of high-resolution melting analysis with direct sequencing for detection of FLT3-TKD, FLT3-ITD and WT1 mutations in acute myeloid leukemia
by: Aida Mahmoudi, et al.
Published: (2021-01-01)

Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy
by: Sankaranarayan Kannan, et al.
Published: (2022-04-01)

Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML
by: Kotoko Yamatani, et al.
Published: (2022-04-01)

Hsa_circ_0015278 Regulates FLT3-ITD AML Progression via Ferroptosis-Related Genes
by: Jiquan Jiang, et al.
Published: (2022-12-01)

First case of AML with rare chromosome translocations: a case report of twins
by: Lin Wang, et al.
Published: (2018-04-01)

Analysis of Chromosomal Aberrations and FLT3 gene Mutations in Childhood Acute Myelogenous Leukemia Patients
by: Ender Coşkunpınar, et al.
Published: (2012-08-01)

Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
by: Yvyin Zhang, et al.
Published: (2023-01-01)

Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance
by: Maximilian Fleischmann, et al.
Published: (2021-11-01)

FLT3-ITD DNA allelic burden, but not mRNA levels, influences the biological characteristics of AML patients
by: Soare Dan S., et al.
Published: (2021-01-01)

FLT3 - ITD positive acute lymphocytic leukemia, does it impact on disease´s course?
by: Sebastian Kobold, et al.
Published: (2010-06-01)

The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia
by: Belen Lopez-Millan, et al.
Published: (2022-03-01)

FLT3 and NPM1 gene mutations in patients with acute myeloid leukemias and the impact of FLT3-ITD mutations on the survival of patients with a normal karyotype
by: Irina Stepanovna Martynkevich, et al.
Published: (2010-12-01)

Frequency of FLT3/ITD Mutation in Patients with Acute Myeloid Leukaemia presenting at Combined Military Hospital, Rawalpindi
by: Anil Babar, et al.
Published: (2023-12-01)

Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches
by: Tecik M, et al.
Published: (2022-11-01)

Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
by: Sebastian Scholl, et al.
Published: (2020-11-01)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
by: Dan Xu, et al.
Published: (2022-07-01)

Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series
by: Ahmad S. Alotaibi, et al.
Published: (2020-10-01)

Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD
by: Sebastian Stasik, et al.
Published: (2022-03-01)

Detection of FLT3 Oncogene Mutations in Acute Myeloid Leukemia Using Conformation Sensitive Gel Electrophoresis
by: Mamdooh Gari, et al.
Published: (2008-11-01)

The Impact of <i>Flt3</i> Gene Mutations in Acute Promyelocytic Leukemia: A Meta-Analysis
by: Gledson L. Picharski, et al.
Published: (2019-09-01)

Gilteritinib Affects the Selection of Dominant Clones in Clonal Hematopoiesis: Sequential Genetic Analysis of an FLT3-ITD Positive AML Patient with Long-Term Gilteritinib Therapy
by: Katagiri S, et al.
Published: (2023-07-01)

Discovery of 5-methyl-N-(2-arylquinazolin-7-yl)isoxazole-4-carboxamide analogues as highly selective FLT3 inhibitors
by: Daseul Im, et al.
Published: (2020-01-01)

A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia
by: Peihong Wang, et al.
Published: (2021-07-01)

<i>FLT3</i>-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification
by: Andrew Y. Li, et al.
Published: (2021-03-01)

Analysis of the presence of FLT3 gene mutation and association with prognostic factors in adult and pediatric acute leukemia patients
by: Graciele Burnatt, et al.
Published: (2017-06-01)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
by: R. Iannotta, et al.
Published: (2022-01-01)

Blocking DNA Damage Repair May Be Involved in Stattic (STAT3 Inhibitor)-Induced FLT3-ITD AML Cell Apoptosis
by: Yuxuan Luo, et al.
Published: (2021-03-01)

Surveying Mutation of FLT3 Genes in Children with Acute Leukemia
by: Maryam Sheikhi, et al.
Published: (2017-02-01)

Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation
by: Konstantin Bogdanov, et al.
Published: (2023-08-01)

GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia
by: Xinhua Xiao, et al.
Published: (2023-11-01)

FLT3‐targeted therapy restores GATA1 pathway function in NPM1/FLT3‐ITD mutated acute myeloid leukaemia
by: D Sorcini, et al.
Published: (2023-11-01)